Recent Updates
Recently added Catalysts

Dermacyd PH_DETINLYN Tangerine Mix

Phase 3

Hygiene | Small molecule | Other |Sanofi|Last Updated: Mar 6, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00785642Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.PHASE3 COMPLETED 30 — — Aug 1, 2008 -Mar 6, 20091 Brazil
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.
From the treatment start to the end of the study
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeSUPPORTIVE_CARE
Treatment Arms
ArmTypeDescription
1EXPERIMENTALDermacyd PH\_DETINLYN Tangerine Mix (Lactic Acid)
Interventions
NameTypeDescription
Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range10 Years — 20 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion criteria: * Integral skin test in the region; * Use of cosmetic product of the same category; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time; Exclusion criteria: * Lactation or gestational risk or gestation; * Use of Anti-i...

Countries:Brazil
Unlock Eligibility Criteria